RMC No. 34-2024 confirms FDA updates to VAT-exempt medicines for cancer, hypertension, and mental illness, with effect from FDA publication.

Businesses selling medicines for cancer, hypertension, and mental illness must immediately check the latest Food and Drug Administration updates to the VAT-exempt product list because VAT exemption takes effect on the date the FDA publishes the updates. RMC No. 34-2024 confirms that the Bureau of Internal Revenue is giving effect to the FDA’s February 5, 2024 endorsement updating the list of VAT-exempt medicines under Republic Act No. 10963, or the TRAIN Law, and Republic Act No. 11534, or the CREATE Act. For pharmacies, drugstores, hospitals, clinics, distributors, and VAT-registered sellers, the practical issue is direct: once a medicine or medical product is covered by the FDA-published update, it must be treated as VAT-exempt from the proper effective date.

What Changed Under RMC No. 34-2024

RMC No. 34-2024 publishes the full text of the February 5, 2024 letter from the Food and Drug Administration of the Department of Health endorsing updates to the list of VAT-exempt products under the TRAIN Law and CREATE Act. The specific category covered by the endorsement is VAT-exempt medicines for cancer, hypertension, and mental illness.

The most important compliance point is not merely that the BIR circulated an FDA endorsement. The most important point is that the BIR reiterates the rule previously clarified in Q&A No. 1 of RMC No. 99-2021: the effectiveness of the VAT exemption for covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the list.

This means businesses should not wait for a separate internal accounting cycle, annual tax review, or supplier confirmation before checking whether a product has been included in the FDA-published updates. The tax treatment depends on whether the item is included in the covered list and when the FDA update was published. The circular is therefore relevant to day-to-day invoicing, point-of-sale configuration, VAT return preparation, inventory tagging, and tax audit defense.

Who Is Affected

RMC No. 34-2024 affects all internal revenue officers and other concerned persons, but its practical business impact falls heavily on entities that sell, distribute, purchase, record, or claim tax treatment for covered medicines. This includes pharmacies, drugstores, hospital pharmacies, clinics, healthcare companies, medicine distributors, wholesalers, importers, and VAT-registered taxpayers whose sales include medicines for cancer, hypertension, or mental illness.

Corporate accountants and CFOs should also treat the circular as a compliance trigger. A VAT-exempt classification changes how a transaction is invoiced, reported, and reconciled. If a covered product continues to be treated as VATable after the FDA-published effective date, the seller may overcharge customers, misclassify sales, and create reconciliation issues in its VAT filings. Conversely, if a product is prematurely treated as VAT-exempt without confirmation that it is included in the FDA-published update, the business may expose itself to deficiency VAT assessments.

For in-house counsel and compliance officers, the search phrases that matter are VAT-exempt medicines Philippines, FDA VAT-exempt products list, RMC 34-2024 VAT exemption, cancer hypertension mental illness VAT exemption, and CREATE Act VAT-exempt medicines. These are the issues clients, finance teams, and BIR examiners are likely to focus on when reviewing sales tax treatment for pharmaceutical products.

Key Compliance Requirement and Effective Date

The key compliance requirement under RMC No. 34-2024 is to align the VAT treatment of covered medicines and medical devices with the FDA-published updates. The BIR specifically states that, as clarified under Q&A No. 1 of RMC No. 99-2021, the effectiveness of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the list.

The document refers to the FDA endorsement letter dated February 5, 2024 and the BIR circular was received for records management on March 5, 2024. The operative rule, however, remains tied to the FDA publication date of the updated list. Businesses must therefore identify the exact FDA publication covering the relevant product and apply VAT exemption from that publication date, not from an arbitrary internal approval date.

RMC No. 34-2024 does not state a new tax rate, threshold, monetary ceiling, or special filing form. It deals with product classification and timing of VAT exemption. The compliance burden is therefore documentary and operational: determine whether the product is included in the FDA update, determine the date of FDA publication, update billing and POS systems, and preserve documentation for audit purposes.

Penalties and Risks for Non-Compliance

RMC No. 34-2024 does not create a separate penalty provision. It also does not state a special surcharge, interest rate, or compromise penalty specific to the updated VAT-exempt list. However, errors in VAT classification can still result in ordinary tax exposure under existing tax rules, especially where a taxpayer fails to properly report VATable and VAT-exempt sales or incorrectly treats transactions in VAT returns and books of accounts.

The most immediate business risk is misclassification. If a product is included in the FDA-published list and the seller continues to impose VAT, the business may face customer disputes, pricing corrections, and accounting adjustments. If the seller treats a product as VAT-exempt without sufficient basis, the BIR may question the exemption during audit and assess deficiency VAT, depending on the facts and records available.

Another risk is poor documentation. For pharmaceutical businesses, it is not enough to simply label a product internally as VAT-exempt. The company should be able to show that the medicine falls within the FDA-endorsed and FDA-published update, that the effective date was correctly applied, and that invoices, official receipts, accounting entries, and VAT returns are consistent with that treatment.

Practical Steps for Businesses

First, businesses should obtain and review the latest FDA-published list of VAT-exempt products covering medicines for cancer, hypertension, and mental illness. The finance team should match the FDA product details against the company’s inventory master list, supplier invoices, product codes, generic names, brand names, and sales classifications.

Second, accounting and tax teams should identify the FDA publication date applicable to each covered product. Because RMC No. 34-2024 reiterates that the VAT exemption is effective on the date of FDA publication of the updates, the effective date should be documented clearly and applied consistently across all branches, POS systems, e-commerce channels, and manual invoicing procedures.

Third, businesses should update invoicing and accounting systems so that covered medicines are treated as VAT-exempt only from the correct date. Any system update should be coordinated among tax, accounting, IT, inventory, and sales personnel. A mismatch between the tax team’s classification and the POS system can create recurring errors across hundreds or thousands of transactions.

Fourth, management should conduct a review of prior transactions involving medicines for cancer, hypertension, and mental illness. If a product became VAT-exempt upon FDA publication but was still treated as VATable afterward, the company should evaluate whether accounting corrections, customer-facing adjustments, or internal tax disclosures are necessary. If a product was treated as VAT-exempt too early, the company should assess the possible VAT exposure and supporting documentation.

Finally, companies should prepare an audit file for RMC No. 34-2024 compliance. This should include the FDA publication relied upon, the product mapping, the date the system change was implemented, sample invoices before and after the effective date, and the accounting treatment in VAT returns. This file can be critical if the BIR later reviews VAT-exempt sales or questions why certain pharmaceutical products were excluded from VATable sales.

How Ablola, Saribong & Gueco Can Help

RMC No. 34-2024 is a reminder that VAT compliance for pharmaceutical and healthcare businesses depends not only on tax law but also on FDA product listings, publication dates, and accurate internal implementation. A small error in product classification can affect pricing, invoicing, VAT reporting, customer relations, and BIR audit exposure.

Ablola, Saribong & Gueco assists pharmacies, healthcare providers, distributors, corporate taxpayers, and in-house finance teams in reviewing VAT-exempt product treatment, preparing tax compliance protocols, responding to BIR examinations, and aligning business operations with BIR issuances such as RMC No. 34-2024. For assistance with VAT-exempt medicines, BIR compliance, and tax audit readiness, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *